Physician profile
Devender G Reddy
NPI 1366415028
$2,804.91
in general payments reported to CMS, 2019-2025
23 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47.41 · 2020: $39.22 · 2021: $20.84 · 2022: $62.36 · 2023: $949 · 2024: $1,126 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,635.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $363.18 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $309.14 | 2023-2025 | |
| Astellas Pharma US INC | $230.21 | 2023-2025 | Veozah |
| Lilly USA, LLC | $222.71 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $219.08 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $201.19 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $157.92 | 2019-2024 | |
| Amgen INC. | $143.69 | 2020-2025 | Evenity, Prolia, Krystexxa |
| Astrazeneca Pharmaceuticals Lp | $136.89 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $133.22 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $118.91 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $99.74 | 2024-2025 | |
| Exact Sciences Corporation | $84.13 | 2023-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $80.94 | 2023-2024 | Heplisav-B |
| Abbott Laboratories | $77.71 | 2023-2025 | Freestyle Libre 3 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $58.43 | 2023 | Austedo, Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.37 | 2023 | |
| Merck Sharp & Dohme LLC | $36.33 | 2024-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Xeris Pharmaceuticals, INC. | $23.57 | 2023 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $21.10 | 2023 | Quviviq |
| Ibsa Pharma INC. | $17.71 | 2024 | Licart, Tirosint |
| Philips North America LLC | $16.67 | 2024 | (Ck7) Extended Holter |
| Biogen, INC. | $16.07 | 2024 | Skyclarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devender Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.